AngioDynamics (ANGO) Reports Q1 Loss, Misses Revenue Estimates

Company Performance - AngioDynamics reported a quarterly loss of $0.11 per share, better than the Zacks Consensus Estimate of a loss of $0.15, and compared to a loss of $0.12 per share a year ago, indicating an earnings surprise of 26.67% [1] - The company posted revenues of $67.49 million for the quarter ended August 2024, missing the Zacks Consensus Estimate by 1.46%, and down from $78.68 million in the same quarter last year [1] - Over the last four quarters, AngioDynamics has surpassed consensus EPS estimates three times, but has only topped consensus revenue estimates once [1] Future Outlook - The current consensus EPS estimate for the coming quarter is -$0.10 on revenues of $71.22 million, and for the current fiscal year, it is -$0.41 on revenues of $284.81 million [4] - The estimate revisions trend for AngioDynamics is currently favorable, resulting in a Zacks Rank 1 (Strong Buy), suggesting that the shares are expected to outperform the market in the near future [4] Industry Context - The Medical - Instruments industry, to which AngioDynamics belongs, is currently in the top 24% of over 250 Zacks industries, indicating a strong performance potential [5] - Another company in the same industry, Integer, is expected to report quarterly earnings of $1.36 per share, reflecting a year-over-year change of +7.1%, with revenues anticipated to be $444.59 million, up 9.9% from the previous year [5][6]